Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Warfarin-4-o-acetyl-arg/asp, its synthesis, activity and application

A technology of warfarin and -asp, applied in drug combination, organic chemistry, metabolic diseases, etc.

Inactive Publication Date: 2021-02-12
CAPITAL UNIVERSITY OF MEDICAL SCIENCES
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it has not been possible

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Warfarin-4-o-acetyl-arg/asp, its synthesis, activity and application
  • Warfarin-4-o-acetyl-arg/asp, its synthesis, activity and application
  • Warfarin-4-o-acetyl-arg/asp, its synthesis, activity and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Embodiment 1 prepares warfarin-4-O-acetic acid benzyl ester

[0022] Put 3.31g (10.00mmol) of warfarin in a 100mL eggplant bottle, add about 40mL of acetone, but it cannot be completely dissolved, heat and stir in an oil bath at 45°C until the warfarin dissolves, add 1.73mL (11.00mmol) of bromine- 2-Benzyl acetate, continue to react in an oil bath at 45°C, and after about 1 hour, a white solid is found attached to the bottle wall. After 48 hours of reaction, the reaction progress was monitored by thin layer chromatography (TLC, petroleum ether / ethyl acetate=2:1), warfarin disappeared, and the colorless solid produced in the reaction was filtered off, and acetone was removed under reduced pressure to obtain a light yellow oil The product was purified by silica gel column chromatography (petroleum ether / ethyl acetate=8:1) to obtain 3.02 g (65%) of the title compound as a colorless solid. ESI-MS(m / e):457[M+H] + ; 1 H-NMR (300MHz, DMSO-d 6 )δ / ppm=7.89(dd,J 1 =3.0Hz,J ...

Embodiment 2

[0023] Embodiment 2 prepares warfarin-4-O-acetic acid

[0024] Dissolve 2.26g (4.95mmol) of warfarin-4-O-benzyl acetate in 20mL of methanol, add 220mg of palladium carbon (Pd / C), under stirring, pump out the air in the water pump, and pass in hydrogen, and repeat the operation Carry out 3 times, and stir at room temperature for 10 h by introducing hydrogen gas. The completion of the reaction was monitored by TLC, Pd / C was removed by filtration, the filtrate was concentrated under reduced pressure to remove the solvent, the residue was solidified with petroleum ether, and washed with anhydrous ether to obtain 1.72 g (93%) of the title compound as a colorless solid. ESI-MS(m / e):367[M+H] + ; 1 H-NMR (300MHz, DMSO-d 6 ):δ / ppm=12.86(s,1H),7.90(d,J=6.0Hz,1H),7.63(t,J=6.0Hz,1H),7.43~7.34(m,4H),7.27(t, J=9.0Hz, 2H), 7.17(t, J=9.0Hz, 1H), 4.99(t, J=9.0Hz, 1H), 4.75(q, J 1 =15.0Hz,J 2 =30.0Hz, 2H), 3.54~3.47(m, 2H), 2.14(s, 3H).

Embodiment 3

[0025] Embodiment 3 prepares warfarin-4-O-acetyl-Arg (NO 2 )-OBzl

[0026] Add 2.03g (5.55mmol) warfarin-4-O-acetic acid into a 100mL eggplant bottle and dissolve it with 30mL dry tetrahydrofuran, add 0.74g (5.48mmol) HOBt and 1.36g ( 6.60mmol) DCC, activated for 45min. A large amount of dicyclohexyl urea (DCU) was precipitated. 2.38g (5.48mmol) Tos Arg (NO 2 )-OBzl was dissolved in 30mL tetrahydrofuran, added to the reaction solution under ice bath, adjusted to pH 8-9 with N-methylmorpholine (NMM), stirred at room temperature for 8 hours, then TLC (dichloromethane / methanol=20:1) monitor the reaction process, the raw material point disappears, filter out DCU, remove the solvent from the filtrate under reduced pressure, dissolve the residue with 50mL ethyl acetate, filter out the insoluble DCU, and use saturated Na 2 CO 3 solution (40mL×3), saturated NaCl solution (40mL×3), saturated KHSO 4 solution (40mL×3), saturated NaCl solution (40mL×3), saturated NaCl 2 CO 3 solu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses warfarin-4-O-acetyl-Arg and warfarin-4-O-acetyl-Asp, discloses their preparation method, discloses their anti-arterial thrombosis activity, discloses their anti-venous Thrombosis activity, discloses their activity of reducing the content of vitamin K in the body, discloses their activity of reducing the content of blood coagulation factor II in the body, discloses their activity of inhibiting platelet aggregation, and thus the present invention discloses their use in the preparation of anti-arterial thrombosis drugs The application, the application in the preparation of anti-venous thrombosis drugs, the application in the preparation of platelet aggregation inhibiting drugs, the application in the preparation of vitamin K antagonists and the application in the preparation of blood coagulation factor II antagonists.

Description

technical field [0001] The present invention relates to warfarin-4-O-acetyl-Arg and warfarin-4-O-acetyl-Asp, to their preparation methods, to their anti-arterial thrombosis activity, to their anti-venous thrombosis activity, to their Their function of reducing the content of vitamin K in the body involves their function of reducing the content of coagulation factor II in the body and their function of inhibiting platelet aggregation. Thus the present invention relates to their application in the preparation of anti-arterial thrombosis drugs, their application in the preparation of anti-venous thrombosis drugs, their application in the preparation of platelet aggregation inhibiting drugs, their use in the preparation of vitamin K antagonists and their use in the preparation of coagulation factor II Antagonist applications. The invention belongs to the field of biomedicine. Background technique [0002] Both arterial thrombosis and venous thrombosis have become diseases with...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D311/56A61P7/02A61P9/10A61P3/00A61P3/02
CPCC07D311/56
Inventor 彭师奇赵明吴建辉王玉记张薪
Owner CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com